Genprex to Present at the August Sidoti Microcap Conference
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Sidoti Microcap Conference on August 15, 2024, at 8:30 am ET. Ryan Confer, the company's President, CEO, and CFO, will provide an overview of Genprex's gene therapies for cancer and diabetes.
The virtual presentation will highlight the company's pioneering work in developing life-changing therapies. Investors can access the presentation through a provided link and schedule virtual meetings with Mr. Confer. An archive of the presentation will be available on the company's website in the Investor Relations section.
This conference appearance underscores Genprex's commitment to advancing its innovative gene therapy pipeline and engaging with the investment community.
Genprex (NASDAQ: GNPX), un'azienda di gene therapy in fase clinica, presenterà alla Sidoti Microcap Conference il 15 agosto 2024 alle 8:30 ora orientale. Ryan Confer, Presidente, CEO e CFO dell'azienda, fornirà una panoramica delle terapie geniche di Genprex per il cancro e il diabete.
La presentazione virtuale metterà in evidenza il lavoro pionieristico dell'azienda nello sviluppo di terapie capaci di cambiare la vita. Gli investitori possono accedere alla presentazione tramite un link fornito e pianificare incontri virtuali con il Signor Confer. Un archivio della presentazione sarà disponibile sul sito web dell'azienda nella sezione Relazioni con gli Investitori.
Questa partecipazione alla conferenza sottolinea l'impegno di Genprex a far avanzare il proprio innovativo portafoglio di terapie geniche e a interagire con la comunità degli investitori.
Genprex (NASDAQ: GNPX), una empresa de terapia génica en etapa clínica, presentará en la Sidoti Microcap Conference el 15 de agosto de 2024 a las 8:30 a. m. ET. Ryan Confer, Presidente, CEO y CFO de la compañía, proporcionará una visión general de las terapias génicas de Genprex para el cáncer y la diabetes.
La presentación virtual destacará el trabajo pionero de la empresa en el desarrollo de terapias que cambian la vida. Los inversores podrán acceder a la presentación a través de un enlace proporcionado y programar reuniones virtuales con el Sr. Confer. Un archivo de la presentación estará disponible en el sitio web de la empresa en la sección de Relaciones con los Inversores.
Esta participación en la conferencia subraya el compromiso de Genprex para avanzar en su innovador pipeline de terapia génica y participar con la comunidad de inversión.
Genprex (NASDAQ: GNPX), 임상 단계의 유전자 치료 회사,는 2024년 8월 15일 오전 8시 30분(동부 시간)에 Sidoti Microcap Conference에 발표할 예정이다. Ryan Confer 회사의 대통령, CEO 및 CFO가 유전자 치료 중 암과 당뇨병을 위한 Genprex의 치료법에 대한 개요를 제공할 것이다.
이번 가상 발표에서는 삶을 변화시키는 치료법 개발에 대한 회사의 선구적인 작업이 강조될 것이다. 투자자들은 제공된 링크를 통해 발표에 접근하고 Confer 씨와 가상 회의를 예약할 수 있다. 발표 아카이브는 회사 웹사이트의 투자자 관계 섹션에 제공될 예정이다.
이번 회의 참여는 Genprex가 혁신적인 유전자 치료 파이프라인을 발전시키고 투자자들과의 소통을 강화하겠다는 약속을 강조하고 있다.
Genprex (NASDAQ: GNPX), une société de thérapie génique en phase clinique, présentera à la Sidoti Microcap Conference le 15 août 2024 à 8h30 ET. Ryan Confer, le président, PDG et directeur financier de la société, fera un aperçu des thérapies géniques de Genprex pour le cancer et le diabète.
La présentation virtuelle mettra en avant le travail pionnier de l'entreprise dans le développement de thérapies qui changent la vie. Les investisseurs peuvent accéder à la présentation via un lien fourni et programmer des réunions virtuelles avec M. Confer. Un enregistrement de la présentation sera disponible sur le site Web de l'entreprise dans la section Relations Investisseurs.
Cette participation à la conférence souligne l'engagement de Genprex à faire avancer son portefeuille de thérapies géniques innovantes et à interagir avec la communauté des investisseurs.
Genprex (NASDAQ: GNPX), ein Unternehmen für gentherapeutische Behandlungen in der klinischen Phase, wird am 15. August 2024 um 8:30 Uhr ET auf der Sidoti Microcap Conference präsentieren. Ryan Confer, der Präsident, CEO und CFO des Unternehmens, wird einen Überblick über Genprex’ gentherapeutische Ansätze für Krebs und Diabetes geben.
Die virtuelle Präsentation wird die wegweisende Arbeit des Unternehmens bei der Entwicklung lebensverändernder Therapien hervorheben. Investoren können über einen bereitgestellten Link auf die Präsentation zugreifen und virtuelle Meetings mit Herrn Confer planen. Ein Archiv der Präsentation wird im Bereich Investor Relations auf der Unternehmenswebsite verfügbar sein.
Dieser Auftritt auf der Konferenz unterstreicht das Engagement von Genprex, sein innovatives Pipeline-Portfolio an Gentherapien voranzutreiben und sich mit der Investoren-Community auseinanderzusetzen.
- None.
- None.
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes
Event: Sidoti Microcap Conference |
Conference Dates: August 14-15, 2024 |
Presentation Date: Thursday, August 15, 2024 |
Presentation Time: 8:30 am ET in Track 3 |
Venue: Virtual |
Presenter: Ryan Confer, Genprex's President, Chief Executive Officer and Chief Financial Officer |
Presentation link: https://bit.ly/3yCCm6W |
Mr. Confer will deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for virtual meetings with investors through the conference platform.
An archive of Mr. Confer's presentation will be available in the Investor Relations section of the Company's website.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-the-august-sidoti-microcap-conference-302217678.html
SOURCE Genprex, Inc.
FAQ
When is Genprex (GNPX) presenting at the Sidoti Microcap Conference?
Who will be presenting for Genprex (GNPX) at the Sidoti Microcap Conference?
What will Genprex (GNPX) discuss in its presentation at the Sidoti Microcap Conference?
Is the Sidoti Microcap Conference where Genprex (GNPX) is presenting a virtual event?
Will investors be able to meet with Genprex (GNPX) management during the Sidoti Microcap Conference?
